Neurology/psychiatricDiamond Therapeutics identifies new 5-HT2A/2C receptor agonistsDiamond Therapeutics Inc. has discovered 5-HT2A and/or 5-HT2C receptor agonists potentially useful for the treatment of epilepsy, pain, and tuberous sclerosis as well as cognitive, neurobehavioral, and mood disorders.